Success Metrics

Clinical Success Rate
88.9%

Based on 16 completed trials

Completion Rate
89%(16/18)
Active Trials
0(0%)
Results Posted
113%(18 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_2
4
22%
Ph phase_1
14
78%

Phase Distribution

14

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
14(77.8%)
Phase 2Efficacy & side effects
4(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(16)
Terminated(2)

Detailed Status

Completed16
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Phase 114 (77.8%)
Phase 24 (22.2%)

Trials by Status

completed1689%
terminated211%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT03230097Phase 2

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Terminated
NCT03351244Phase 2

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Terminated
NCT02438683Phase 1

BI 409306 Cardiac Safety Trial in Healthy Volunteers

Completed
NCT03505151Phase 1

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Completed
NCT02635750Phase 1

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Completed
NCT02222168Phase 1

Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers

Completed
NCT01892384Phase 1

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

Completed
NCT01343706Phase 1

Safety Tolerability and Pharmacokinetic of BI 409306

Completed
NCT02248259Phase 1

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Completed
NCT01493570Phase 1

Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers

Completed
NCT03193307Phase 1

This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other

Completed
NCT03934203Phase 1

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Completed
NCT04602221Phase 1

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Completed
NCT01611311Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306

Completed
NCT01505894Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

Completed
NCT03151499Phase 1

Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers

Completed
NCT02240693Phase 2

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Completed
NCT02337907Phase 2

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18